Coherus Biosciences | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.13B 55.39M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amarin USD 655.68M 29.67M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Baxter International USD 25.78B 894M 2024-12
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Eli Lilly USD 89.39B 10.67B 2025-03
Fujifilm JPY 5.25T 29.02B 2025-03
Gilead Sciences USD 56.43B 2.56B 2025-03
Ironwood Pharmaceuticals USD 351.3M 38.22M 2024-12
Merck USD 115.12B 1.98B 2025-03
Myriad Genetics USD 1.01B 21.5M 2025-03
Pacira USD 1.59B 33.15M 2025-03
Perrigo USD 9.76B 112.1M 2025-03
Pfizer USD 208.03B 5.37B 2025-03
PTC Therapeutics USD 2.66B 950.36M 2025-03
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Sarepta Therapeutics USD 3.47B 497.79M 2025-03
Teva Pharmaceutical Industries USD 38.42B 911M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12
Xencor USD 904.69M 47.26M 2025-03
Zoetis USD 14.1B 139M 2025-03



Coherus Biosciences Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.